Why Compare Ipamorelin and Hexarelin for Post-Workout GH
Growth hormone secretagogues draw steady interest in performance circles. Two names surface often: Ipamorelin and Hexarelin. Both aim to amplify the body's own GH output, but they differ in ways that matter for athletes. The key question is which one raises GH without dragging prolactin or cortisol along for the ride.
Post-workout, the GH pulse is already primed. Adding a peptide could extend that window. Yet not all GH pulses are clean. Some peptides trigger a broader hormonal cascade. Hexarelin, for example, can spike prolactin and cortisol. Ipamorelin is often described as more selective. This comparison digs into the evidence behind that claim.
Anti-doping rules under WADA prohibit GH secretagogues. Athletes subject to testing must know these compounds are banned. This article frames the science, not a recommendation. We look at what published studies say about GH release, side-effect profiles, and where each peptide is studied more.
Ipamorelin: A Selective GH Pulse with Minimal Sides
Ipamorelin is a pentapeptide that binds the ghrelin receptor. It triggers GH release without much effect on other hormones. In a 2001 study in Endocrinology, Raun and colleagues showed Ipamorelin's selectivity in rats. GH rose significantly, while prolactin and cortisol stayed near baseline. This is a 2 of 3 on evidence quality for human relevance, given the animal model.
Human data also point to a clean profile. A 1998 paper in Clinical Endocrinology by Johansen et al. tested Ipamorelin in healthy men. GH increased in a dose-dependent way. Prolactin and cortisol levels did not budge much, even at higher doses. That selectivity is Ipamorelin's calling card.
For post-workout use, the idea is to piggyback on the natural GH surge. Ipamorelin's pulse is short-lived, peaking around 30-45 minutes after administration. It does not seem to desensitize the receptor over time, at least in short-term studies. This is a 2 of 3 on evidence quality, as long-term human data are thin.
Cost-wise, Ipamorelin runs something like $40-60 per vial from research suppliers. A typical study protocol might use 200-300 mcg per administration, making a vial last maybe two weeks. That puts monthly research costs in the neighbourhood of $120-180.
Hexarelin: Potent GH Release with Hormonal Trade-offs
Hexarelin is a hexapeptide and a strong GH secretagogue. It also acts on the ghrelin receptor but with less selectivity. In a 1997 paper in European Journal of Endocrinology, Arvat and colleagues found Hexarelin produced a robust GH response in humans. However, prolactin and cortisol also climbed. That is a consistent finding across studies.
The GH spike from Hexarelin can be larger than Ipamorelin's. Some data suggest a 2-3 fold higher peak. But the prolactin rise is a concern. Elevated prolactin can dampen libido and mood, which are performance-relevant. Cortisol spikes may counteract some anabolic effects. This is a 2 of 3 on evidence quality, as most studies are small and short-term.
Hexarelin also shows some cardiac effects. Research in Journal of Clinical Endocrinology & Metabolism by Bisi et al. (1999) noted left ventricular ejection fraction improvements in patients. That might interest athletes, but the hormone trade-offs remain. For post-workout use, the cortisol bump could blunt recovery, making the net effect less clear.
Hexarelin is similarly priced, around $45-65 per vial. Dosing in studies often falls in the 100-200 mcg range. Monthly research costs might be similar to Ipamorelin, but the side-effect profile adds complexity.
Head-to-Head: GH Output and Prolactin Spikes
Direct comparisons are scarce. One study by Ghigo et al. in Neuroendocrinology (1999) tested multiple secretagogues including both. Hexarelin produced a higher GH peak but also a clear prolactin rise. Ipamorelin's GH response was lower but without the prolactin bump. That pattern holds across the literature.
For athletes, the cleaner GH pulse may be more valuable. Prolactin spikes can interfere with testosterone production and mood. Cortisol spikes can promote muscle breakdown. Ipamorelin's selectivity makes it a 2 of 3 on evidence quality for a favourable side-effect profile. Hexarelin's potency comes with a 1 of 3 on evidence quality for clean GH release.
Combining Ipamorelin with CJC-1295 is common in research. CJC-1295 extends the GH pulse, while Ipamorelin triggers it. This pairing avoids prolactin issues. Hexarelin plus CJC-1295 would likely amplify prolactin and cortisol, making it less attractive. No published studies directly test these combos in athletes, so this is a 1 of 3 on evidence quality.
MK-677 and GHRP-6 are other ghrelin agonists. MK-677 is oral and long-acting but also raises prolactin and cortisol. GHRP-6 is more like Hexarelin in its side effects. IGF-1 LR3 is downstream of GH and bypasses these issues but carries its own risks. The choice among these depends on the goal: pure GH elevation or downstream anabolism.
Where Each Peptide Is Studied More
Ipamorelin research focuses on selectivity and long-term safety. Animal studies suggest it does not desensitize the receptor. Human trials are mostly in GH-deficient populations. Performance-specific data are lacking. This is a 1 of 3 on evidence quality for athletic contexts.
Hexarelin has more cardiac research. Its effects on heart function are well-documented in small human studies. That might make it interesting for recovery from intense training, but the hormonal side effects muddy the picture. Again, performance data are absent. This is a 1 of 3 on evidence quality for post-workout use.
Both peptides are banned by WADA under category S2.2. Athletes should be aware that detection windows exist. Research on detection methods is ongoing. The anti-doping context means these compounds carry legal and career risks for competitors.
In summary, Ipamorelin offers a cleaner GH pulse with fewer hormonal side effects. Hexarelin delivers a bigger GH spike but with prolactin and cortisol trade-offs. The evidence quality for both in performance settings is low. More human research is needed to understand long-term effects and real-world outcomes.
Information here reflects published findings at the time of writing and may be superseded by newer research.